FDA APPROVES EXPANDED USE OF ECULIZUMAB (SOLIRIS) FOR PEDIATRIC MYASTHENIA GRAVIS, BRINGING NEW TREATMENT OPTIONS FOR CHILDREN
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.